Tenax Therapeutics is trading 10.33% up at $2.35 after presenting detailed Phase 3 LEVEL results at the European Society of Cardiology Congress on August 29, 2026.

  • The trial missed its primary endpoint, but patients below the median walking distance showed improved exercise capacity, lower NT-proBNP, and reduced RVSP.
  • Company-specific data appears to be driving renewed investor interest following the earlier sell-off.